Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avience BiomedicalsNSE:AVIENCE -0.38%18 Net Margin % is 15.99% as of Mar. 2025, which is 79% above its 10-year median of 8.93. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Avience Biomedicals ranks better than 84.09% on this metric.
The historical rank and industry rank for Avience Biomedicals's Net Margin % or its related term are showing as below:
NSE:AVIENCE'
s Net Margin % Range Over the Past 10 Years
Min: 6.48 Med: 8.93 Max: 15.99
Current: 15.99
NSE:AVIENCE's Net Margin % is ranked better than 84.09% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.2
vs NSE:AVIENCE: 15.99
Avience Biomedicals (NSE:AVIENCE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Avience Biomedicals Net Margin % Related Terms
Avience Biomedicals Net Margin % Historical Data
* Premium members only.
The historical data trend for Avience Biomedicals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals Net Margin % Chart
Avience Biomedicals Annual Data
Trend
Mar23
Mar24
Mar25
Net Margin %
6.48
8.93
15.99
Avience Biomedicals Semi-Annual Data
Mar23
Mar24
Mar25
Net Margin %
6.48
8.93
15.99
NSE:AVIENCE vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Avience Biomedicals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avience Biomedicals Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Avience Biomedicals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals (NSE:AVIENCE) has a Net Margin % of 15.99% as of Mar. 2025. Net margin is the ratio of total net income to net sales. View historical data on Avience Biomedicals and its competitors. This is 79% above median its historical median of 8.93. Over the past decade, Avience Biomedicals' Net Margin % has ranged from 6.48 to 15.99. According to the industry distribution chart, Avience Biomedicals ranks #130 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 15.9%.
Is Avience Biomedicals' Net Margin % too high?
Avience Biomedicals' current Net Margin % of 15.99% is 79% above median its 10-year median of 8.93. Over the past 10 years, this metric has ranged from a low of 6.48 to a high of 15.99. The Medical Devices & Instruments industry median Net Margin % is 2.20. Avience Biomedicals' value of 15.99% is 626.8% above this industry median. Based on the distribution chart, Avience Biomedicals ranks #130 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #130 out of 817 companies for Net Margin %. This places Avience Biomedicals in the top 16% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.20. Avience Biomedicals' value of 15.99% is 626.8% above this benchmark. Historically, Avience Biomedicals' own Net Margin % has ranged from 6.48 to 15.99 over the past decade. While the company's 10-year median is 8.93 vs. the industry median of 2.20, Avience Biomedicals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.20, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avience Biomedicals's current Net Margin % of 15.99% is 626.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Avience Biomedicals and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current Net Margin % is 15.99%, which is 79% above median its own 10-year median of 8.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Net Margin % of 15.99%. The current Net Margin % is 15.99%, which is 79% above median its 10-year median of 8.93 and 626.8% above the Medical Devices & Instruments industry median of 2.20. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Net Margin % is 15.99% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score
Get the complete analysis for NSE:AVIENCE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AVIENCE has been successfully added to your 
